Stock Events

Astrazeneca 

$128.5
135
+$1.4+1.1% Tuesday 20:47

Statistics

Day High
129.9
Day Low
128.12
52W High
153.1
52W Low
118.16
Volume
1,797
Avg. Volume
3,756
Mkt Cap
219.4B
P/E Ratio
0
Dividend Yield
2.24%
Dividend
2.88

Upcoming

Dividends

2.24%Dividend Yield
Sep 23
$0.91
Mar 23
$1.96
Sep 22
$0.93
Mar 22
$1.94
Sep 21
$0.89

Earnings

26AprExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
0.36
0.71
1.07
Expected EPS
1.01
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AZNCF. It's not an investment recommendation.

About

Pharmaceuticals: Major
Health Technology
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Show more...
CEO
Mr. Pascal Soriot D.V.M., M.B.A.
Employees
83100
Country
UK
ISIN
GB0009895292
WKN
000886455

Listings